CALC CalciMedica, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY34.5%
TTM EPS YoY152.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-763.3%
ROA-103.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.4%
Debt / equity0.00x
Current ratio4.96x
Interest coverage-14.15x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio21.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $2.32M | $2.10M | $3.48M | $3.11M | $3.85M | $4.05M | $4.22M | $3.83M |
| SG&A expense | $2.43M | $1.91M | $2.13M | $1.28M | $1.77M | $2.57M | $2.27M | $2.34M |
| Operating income | -$4.75M | -$4.01M | -$5.61M | -$4.38M | -$5.62M | -$6.62M | -$6.50M | -$6.17M |
| Interest expense | $357,000 | $325,000 | $319,000 | $325,000 | $326,000 | $324,000 | $447,000 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.67M | -$7.65M | $4.98M | -$10.76M | -$7.80M | -$5.96M | -$5.04M | -$4.26M |
| EBITDA | -$4.74M | -$4.00M | -$5.60M | -$4.38M | -$5.61M | -$6.61M | -$6.48M | -$6.16M |
| EPS (basic) | -0.24 | -0.45 | 0.31 | — | -2.59 | -0.40 | -0.36 | — |
| EPS (diluted) | -0.24 | -0.45 | 0.30 | — | -2.59 | -0.40 | -0.36 | — |
| Weighted avg. shares (diluted) | 6.91M | 17.10M | 16.33M | — | 3.02M | 15.00M | 14.12M | — |
| Banking | ||||||||
| Noninterest income | $134,000 | $54,000 | $106,000 | $151,000 | $140,000 | $220,000 | $202,000 | $214,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $4.57M | $18.62M | $8.16M | $11.52M | $5.47M | $5.92M | $12.56M | $7.93M |
| Short-term investments | $9.19M | $0 | $0 | $1.50M | $8.61M | $12.04M | $12.07M | $10.73M |
| Current assets | $14.22M | $19.46M | $8.55M | $13.53M | $14.85M | $18.96M | $25.22M | $19.66M |
| PP&E, net | $72,000 | $36,000 | $43,000 | $50,000 | $49,000 | $105,000 | $118,000 | $119,000 |
| Total assets | $14.29M | $19.50M | $8.61M | $13.59M | $14.91M | $19.08M | $25.35M | $19.79M |
| Current liabilities | $2.87M | $3.49M | $5.31M | $3.78M | $3.68M | $3.48M | $4.46M | $3.68M |
| Total liabilities | $10.07M | $13.99M | $9.71M | $20.23M | $15.18M | $12.98M | $14.46M | $5.38M |
| Shareholders' equity | $4.23M | $5.51M | -$1.10M | -$6.64M | -$268,000 | $6.10M | $10.89M | $14.41M |
| Shares outstanding | 6.89M | 30.74M | 15.75M | 3.09M | 14.26M | 13.97M | 13.97M | 13.48M |
| Cash flow statement | ||||||||
| Operating cash flow | -$3.86M | -$4.62M | -$4.86M | -$4.85M | -$4.78M | -$6.67M | -$4.88M | -$4.97M |
| Capital expenditure | $0 | $0 | $0 | $6,000 | $8,000 | $5,000 | $9,000 | $2,000 |
| Free cash flow | -$3.86M | -$4.62M | -$4.86M | -$4.86M | -$4.79M | -$6.67M | -$4.89M | -$4.97M |
| Investing cash flow | -$9.14M | $42,000 | $1.50M | $7.15M | $3.51M | $134,000 | -$1.24M | -$5.17M |
| Financing cash flow | -$1.04M | $15.03M | $0 | $3.75M | $818,000 | -$102,000 | $10.74M | $8.92M |
| Depreciation & amortization | $7,000 | $7,000 | $7,000 | $5,000 | $12,000 | $14,000 | $15,000 | $14,000 |
| Stock-based compensation | $496,000 | $540,000 | $561,000 | $622,000 | $625,000 | $1.18M | $549,000 | $632,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.